Premium
Invega: prolonged‐release paliperidone for schizophrenia
Author(s) -
Chaplin Steve,
Livingston Martin
Publication year - 2008
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.195
Subject(s) - paliperidone , medicine , schizophrenia (object oriented programming) , paliperidone palmitate , adverse effect , extended release , antipsychotic , psychiatry , psychotherapist , pharmacology , psychology
Paliperidone (Invega) is a new atypical antipsychotic available as modified‐release tablets for once‐daily administration. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse affects, and Dr Martin Livingston comments on its place in the treatment of schizophrenia. Copyright © 2008 Wiley Interface Ltd